Mario Gaudino1, Christopher Lau1, Monica Munjal1, Dimitrios Avgerinos1, Leonard N Girardi2. 1. Department of Cardiothoracic Surgery, Weill Cornell Medical College, New York, NY. 2. Department of Cardiothoracic Surgery, Weill Cornell Medical College, New York, NY. Electronic address: lngirard@med.cornell.edu.
Abstract
OBJECTIVE: The study objective was to give an overview of the current state of the art of the surgical treatment of aortic root pathologies in a high-volume center. METHODS: From May 1997 to January 2014, aortic root replacement was performed in 890 consecutive patients; 289 received a mechanical composite valved graft, 421 received a biologic composite valved graft, and 180 received a valve-sparing reconstruction. Propensity matching analysis was used to neutralize the differences in baseline characteristics between patients assigned to the different procedures. RESULTS: Operative mortality was 0.2% (0% in the valve-sparing reconstruction group); the incidence of major postoperative complications was less than 0.5%. Predictors of adverse in-hospital outcome were age, nonelective operation, renal status, reoperation, New York Heart Association class, ejection fraction, and concomitant procedures. Five-year survival was 89.4%. Previous myocardial infarction, preoperative renal status, redo operation, and concomitant procedures were significantly associated with follow-up death. In the propensity-matched groups, the type of operation performed did not affect in-hospital and late outcome. Aortic reintervention rates at 5 years were 0% for the mechanical composite valved graft group, 2.4% for the biologic composite valved graft group, and 7.3% for the valve-sparing reconstruction series. CONCLUSIONS: In the current era, aortic root replacement can be performed with low perioperative risk in high-volume aortic centers. The type of operation performed does not affect early or late survival. Although the mechanical composite valved graft remains the gold standard for durability, the biologic composite valved graft and valve-sparing reconstruction are excellent options for those who cannot take or want to avoid long-term anticoagulation.
OBJECTIVE: The study objective was to give an overview of the current state of the art of the surgical treatment of aortic root pathologies in a high-volume center. METHODS: From May 1997 to January 2014, aortic root replacement was performed in 890 consecutive patients; 289 received a mechanical composite valved graft, 421 received a biologic composite valved graft, and 180 received a valve-sparing reconstruction. Propensity matching analysis was used to neutralize the differences in baseline characteristics between patients assigned to the different procedures. RESULTS: Operative mortality was 0.2% (0% in the valve-sparing reconstruction group); the incidence of major postoperative complications was less than 0.5%. Predictors of adverse in-hospital outcome were age, nonelective operation, renal status, reoperation, New York Heart Association class, ejection fraction, and concomitant procedures. Five-year survival was 89.4%. Previous myocardial infarction, preoperative renal status, redo operation, and concomitant procedures were significantly associated with follow-up death. In the propensity-matched groups, the type of operation performed did not affect in-hospital and late outcome. Aortic reintervention rates at 5 years were 0% for the mechanical composite valved graft group, 2.4% for the biologic composite valved graft group, and 7.3% for the valve-sparing reconstruction series. CONCLUSIONS: In the current era, aortic root replacement can be performed with low perioperative risk in high-volume aortic centers. The type of operation performed does not affect early or late survival. Although the mechanical composite valved graft remains the gold standard for durability, the biologic composite valved graft and valve-sparing reconstruction are excellent options for those who cannot take or want to avoid long-term anticoagulation.
Authors: Lukas Schamberger; Sergey Leontyev; Piroze Minoo Davierwala; Konstantin Von Aspern; Sven Lehmann; Martin Misfeld; Michael Andrew Borger Journal: Indian J Thorac Cardiovasc Surg Date: 2019-10-14
Authors: Servet Ergün; Mehmet Dedemoğlu; Murat Bülent Rabuş; Baburhan Özbek; Mustafa Mert Özgür; Mehmet Altuğ Tuncer; Mehmet Balkanay; Mehmet Kaan Kirali Journal: Cardiovasc J Afr Date: 2018-06-26 Impact factor: 1.167
Authors: Ziv Beckerman; Michael O Kayatta; LaRonica McPherson; Jose N Binongo; Yi Lasanajak; Bradley G Leshnower; Edward P Chen Journal: J Vis Surg Date: 2018-05-14
Authors: Fabrício José Dinato; Ricardo Ribeiro Dias; José Augusto Duncan; Fábio Fernandes; Felix José Alvares Ramirez; Charles Mady; Fabio B Jatene Journal: Braz J Cardiovasc Surg Date: 2020-12-01